15:30 , May 25, 2018 |  BC Week In Review  |  Clinical News

Nabriva's lefamulin meets in Phase III LEAP 2 trial for CABP

Nabriva Therapeutics plc (NASDAQ:NBRV) reported a higher incidence of GI adverse events in patients who received oral lefamulin (BC-3781) in the Phase III LEAP 2 trial to treat moderate community-acquired bacterial pneumonia (CABP). While the...
00:36 , May 25, 2018 |  BC Innovations  |  Product R&D

Peptides step up

New screening platforms and synthetic approaches could finally solve some of the longstanding hurdles to turning antimicrobial peptides into therapeutic candidates to combat antibacterial resistance, overcoming their history of limited clinical efficacy, systemic toxicity and...
22:45 , May 21, 2018 |  BC Extra  |  Clinical News

Nabriva falls on GI safety in second Phase III for CABP

Nabriva Therapeutics plc (NASDAQ:NBRV) lost $0.90 (17%) to $4.53 on Monday after reporting a higher incidence of GI adverse events in patients who received oral lefamulin (BC-3781) in the Phase III LEAP 2 trial to...
16:58 , Mar 22, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Escherichia Cell culture studies suggest an antimicrobial peptide inhibitor of the bacterial ribosomal 50S subunit could help treat E. coli infection. An in silico screen of the genome of the bottlenose dolphin Tursiops truncatus...
00:35 , Oct 13, 2017 |  BC Week In Review  |  Clinical News

Melinta reports Phase I data for acne candidate radezolid

Melinta Therapeutics Inc. (New Haven, Conn.) reported data from a Phase I trial in 10 patients with mild to moderate acne vulgaris showing that twice-daily topical radezolid (RX-1741) for 4 weeks was well tolerated with...
20:11 , Sep 22, 2017 |  BC Week In Review  |  Clinical News

Nabriva's lefamulin meets in Phase III LEAP 1 trial for CABP

Nabriva Therapeutics plc (NASDAQ:NBRV) reported that IV-to-oral lefamulin (BC-3781) met the FDA- and EMA-defined primary endpoints in the double-blind, international Phase III LEAP 1 trial to treat moderate to severe community-acquired bacterial pneumonia (CABP). Top-line...
19:47 , Sep 20, 2017 |  BC Extra  |  Financial News

Nabriva raises $80M in follow-on

Nabriva Therapeutics plc (NASDAQ:NBRV) raised $80 million through the sale of 9.4 million shares at $8.50 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, SunTrust Robinson Humphrey, Needham and Wedbush. The price is...
20:24 , Sep 18, 2017 |  BC Extra  |  Clinical News

Nabriva rises on Phase III CABP success

Nabriva Therapeutics plc (NASDAQ:NBRV) jumped $2.01 (29%) to $8.87 on Monday after reporting that IV-to-oral lefamulin (BC-3781) met the FDA- and EMA-defined primary endpoints in the Phase III LEAP 1 trial to treat moderate to...
00:19 , May 19, 2017 |  BC Week In Review  |  Clinical News

Cempra withdraws Solithera MAA

Cempra Inc. (NASDAQ:CEMP) withdrew an MAA for oral and IV formulations of Solithera solithromycin (CEM-101) to treat community-acquired bacterial pneumonia (CABP) after receiving EMA’s Day 120 questions. The company believes EMA will require additional data...
23:13 , Apr 13, 2017 |  BC Week In Review  |  Clinical News

Lefamulin: Completed Ph III enrollment

Nabriva completed enrollment of 550 patients in the double-blind, international Phase III LEAP 1 trial comparing IV and oral lefamulin vs. IV and oral moxifloxacin with or without Zyvox linezolid for 7 or 10 days....